Emma Searle, PhD, consultant hematologist, The Christie Hospital NHS Foundation Trust, touches on key points learnt from MajesTEC-2 data and other data to look forward to at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.
This is an exciting time to be working in the myeloma space, said Emma Searle, PhD, consultant hematologist, The Christie Hospital NHS Foundation Trust. Searle will be presenting data from a part of the MajesTEC-2 study on teclistamab in combination with daratumumab and lenalidomide in patients with relapsed multiple myeloma at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 10-13, 2022, in New Orleans, Louisiana.
Transcript
What will be the most important takeaways from the MajesTEC-2 study data presented at the ASH Annual Meeting and Exposition?
The key points that we've learnt from the MajesTEC-2 data, in addition to what we had already been learning from MajesTEC-1, are that teclistamab is a very powerful antimyeloma therapy with a novel mechanism of action that has the potential to induce rapid and deep responses in patients with relapsed multiple myeloma. The patient population in MajesTEC-2 was less heavily pretreated than the patient population in MajesTEC-1, and we're seeing very high overall response rates in this combination of near to 94% across the 2 different dosing schedules. Those responses appear to deepen over time. This isn't mature data, but I think the promise is certainly that.
What data are you looking forward to seeing at ASH?
For me as a phase 1 trialist, it's always looking at the novel agents coming through in that space. This is a great time to be a clinical trialist in myeloma. We've got a large number of exciting agents with novel targets. The immunotherapies, obviously, are particularly exciting. And myeloma is still not a curable condition, but I think we're really making progress now in terms of discovering alternative methods of treating myeloma with the potential to achieve deep and durable responses. This really is an exciting time to be working in this space.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More